Can a single shot build a cancer army inside the body?
NCT ID NCT07735533
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma, who have few other options. The goal is to see if this approach is safe and can shrink or eliminate tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a gene therapy that creates CD22-directed CAR T cells inside the body, given with rapamycin
- What this could lead to
- If it works, this could offer a one-time treatment option for people with hard-to-treat B-cell lymphomas, potentially eliminating the need for repeated infusions of lab-made CAR T cells.
- What could go wrong
- This is an early-phase trial, so safety and effectiveness are not yet known. The therapy may cause severe side effects, including immune reactions or organ damage, and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a simple blood test spot lymphoma earlier?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- What happens years after CAR-T therapy? a study aims to find out
- Can a smart immune cell with a kill switch beat tough lymphomas?